YL 90148
Alternative Names: YL-90148Latest Information Update: 24 Jan 2023
At a glance
- Originator Shanghai Yingli Pharmaceutical
- Class Antigouts; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gout; Hyperuricaemia
Most Recent Events
- 24 Jan 2023 YL 90148 is still in phase II clinical trial in Gout and Hyperuricaemia in China (Shanghai Yingli Pharmaceutical pipeline, January 2023)
- 23 Dec 2020 Phase-II clinical trials in Gout in China (PO) (Shanghai Yingli Pharmaceutical pipeline, December 2020)
- 23 Dec 2020 Phase-II clinical trials in Hyperuricaemia in China (PO) (Shanghai Yingli Pharmaceutical pipeline, December 2020)